Sort   by:  
 Page size 
ProteomicsEffect of CDK7 inhibitor, FHD-286, SNDX-50469, or Tasquinimod on protein expression alterations in patient-derived secondary AML or de novo MLL1-rearranged AML cells
Patient-derived secondary AML cells were treated with 100 nM of SY-5609 for 24 hours, 100 nM of FHD-286 for 48 hours, or 20 µM of Tasquinimod for 48 hours to determine the global protein expression alterations that correlate with the cell cycle, growth inhibitory and lethal effects of treatment with...
ORGANISM(S): Homo sapiens (Human) 
2025-04-28 | PXD053548 | Pride
Secondary aml Sndx-50469 Tasquinimod Cdk7 inhibitor Fhd-286 
ProteomicsEffect of CDK7 inhibitor on protein expression alterations in cultured secondary AML HEL92.1.7 cells
HEL92.1.7 cells in exponential growth phase were treated with 100 nM of SY-5609 for 24 hours to determine the global protein expression alterations that correlate with the cell cycle, growth inhibitory and lethal effects of treatment with a CDK7 inhibitor in secondary AML cells.
ORGANISM(S): Homo sapiens (Human) 
2025-04-28 | PXD053572 | Pride
Secondary aml Cdk7 inhibitor C-myc 
UnknownEarly exposure of infants to natural rotavirus infection: a review of studies with human rotavirus vaccine RIX4414.
Not available
S-EPMC4261882 | biostudies-literature
UnknownReal-world treatments and thrombotic events in polycythemia vera patients in the USA.
Not available
S-EPMC9977710 | biostudies-literature
UnknownTargeting the p-D-C: easy as C-D-1-2-3?
Not available
S-EPMC7955405 | biostudies-literature
UnknownResource utilization and inpatient hospitalization costs associated with thromboembolic events among patients with polycythemia vera.
Not available
S-EPMC11879438 | biostudies-literature
UnknownEfficacy and manageable safety of tagraxofusp in blastic plasmacytoid dendritic cell neoplasm: a case series of pediatric and adolescent/young adult patients.
Not available
S-EPMC10887247 | biostudies-literature
UnknownClearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.
Not available
S-EPMC6008108 | biostudies-literature
UnknownInotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia.
Not available
S-EPMC9096877 | biostudies-literature
UnknownHow to Treat Adult Acute Myeloid Leukemia: An Evolving Paradigm.
Not available
S-EPMC8702813 | biostudies-literature
Sort   by:  
 Page size